Edoxaban (Lixiana®)
Last Updated: 20th January, 2017

This Effective Shared Care Agreement Toolkit (edoxaban [Lixiana®]) is designed to assist healthcare professionals in the development of their own shared care agreements to support locally agreed policy on the prescribing of edoxaban for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. In particular, it suggests ways in which responsibilities can be shared between the secondary care specialist and general practitioner (GP) / primary care prescriber. The Toolkit is intended to act as a flexible template that enables users to consider suggested content and tailor it to local circumstances and requirements.

Please note that the Effective Shared Care Agreement Toolkit is not a recommendation to prescribe edoxaban. The decision to prescribe edoxaban is the responsibility of the respective local healthcare organisation and the Toolkit should only be used after the local decision to prescribe edoxaban has been taken.

To support your local decision-making you may wish to refer to:

Further support materials are available from the manufacturer:

The Effective Shared Care Agreement Toolkit and Keele University's work in developing shared care resources has been recognised by the General Medical Council in their guidance 'Good practice in prescribing and managing medicines and devices' (January 2013).

Keele University is not responsible for the content of any linked site or manufacturer's material. Listing and linking should not be taken as an endorsement of any kind and we accept no liability in respect of the content.

Enter the
ESCA Toolkit

Agreement Library

Upload an existing agreement to the library here.


Supported by an unrestricted grant provided by Daiichi-Sankyo in the UK